Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|March 19, 2020
Folded or Degraded in Endoplasmic ReticulumChushu Li, Bingqing Xia, Sheng Wang, et al.Gastrointestinal Tumors|October 27, 2017
Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein ActivationChushu Li, Huanbin Wang, Han Yao, et al.Oncogene|December 16, 2020
Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunityChushu Li, Han Yao, Huanbin Wang, et al.Frontiers in Immunology|August 15, 2018
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial ImmunotherapyHan Yao, Huanbin Wang, Chushu Li, et al.Frontiers in Pharmacology|June 19, 2018
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune EvasionYiting Wang, Huanbin Wang, Han Yao, et al.Oncogene|April 20, 2026
MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRCChushu Li, Shouyan Deng, Minxian Zhuang, et al.Oncoimmunology|August 17, 2017
PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylationHuanbin Wang, Han Yao, Chushu Li, et al.Nature Chemical Biology|November 7, 2018
HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicityHuanbin Wang, Han Yao, Chushu Li, et al.Journal for Immunotherapy of Cancer|August 3, 2021
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapyChushu Li, Hao Chi, Shouyan Deng, et al.EMBO Molecular Medicine|May 15, 2026
Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasionShouyan Deng, Yuan Fang, Jieyuan Xue, et al.Pageof 2